Global Drivers Analysis: The Rapid Evolution of the Next-Generation Sequencing (NGS) Market in Precision Medicine

The next-generation sequencing (NGS) market within precision medicine is set to experience significant expansion as advancements in technology and new applications continue to emerge. This growth promises to reshape how personalized treatments are developed and delivered, driven by innovations in genomic analysis and collaboration across the healthcare sector. Below is a detailed overview of the market size, key players, emerging trends, and segmentation of the NGS in precision medicine industry.

Projected Market Size and Growth Dynamics for NGS in Precision Medicine
The next-generation sequencing in precision medicine market is anticipated to grow rapidly, reaching a valuation of $14.05 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 16.9% over the forecast period. Several factors are driving this growth, including continuous technological advancements in sequencing instruments, the incorporation of artificial intelligence (AI) into genomics, the rise of cloud-based sequencing services, increasing partnerships between pharmaceutical and biotechnology firms, and the expansion of precision medicine across emerging regions. Leading trends shaping the market include AI-driven genomic analysis, cloud-enabled sequencing solutions, broader adoption of personalized medicine, automated sequencing workflows, and real-time interpretation of genomic data.

Download a free sample of the next-generation sequencing (ngs) in precision medicine market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28280&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Mar_PR

Prominent Companies Leading the NGS in Precision Medicine Industry
The market landscape features a number of influential players who are actively shaping innovation and competition. Key companies include Thermo Fisher Scientific Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Natera Inc., Tempus Labs Inc., 10x Genomics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences Inc., Fulgent Genetics Inc., Twist Bioscience Corporation, Pacific Biosciences of California Inc., Macrogen Inc., Ultima Genomics Inc., Personalis Inc., Element Biosciences Inc., Genomenon Inc., Strand Life Sciences Pvt. Ltd., and Singular Genomics Systems Inc.

Significant Collaborations Advancing NGS Applications
In a notable development in June 2025, Qiagen N.V., a German company specializing in sample and assay technologies crucial to NGS solutions in precision medicine, partnered with the US-based biopharmaceutical company Incyte Corporation. This collaboration focuses on creating a multimodal NGS companion diagnostic panel designed to accurately detect mutant CALR and other genetic mutations in patients with myeloproliferative neoplasms (MPNs). The diagnostic tool aims to guide patient selection and support Incyte's targeted therapies, thereby improving patient outcomes on a global scale.

View the full next-generation sequencing (ngs) in precision medicine market report:
https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-ngs-in-precision-medicine-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Mar_PR

Emerging Innovations and Trends in the NGS Precision Medicine Market
Companies in the NGS segment are increasingly focusing on sophisticated solutions such as multimodal DNA and RNA library kits to enhance the precision and efficiency of genomic analysis. These kits facilitate simultaneous preparation of sequencing libraries for both DNA and RNA within a single workflow, allowing comprehensive genome and transcriptome analysis.

For example, in May 2024, Qiagen N.V. introduced the QIAseq Multimodal DNA and RNA Library Kit. This next-generation sequencing product simplifies multiomic research by enabling combined DNA and RNA library preparation from a single sample. It supports whole genome and whole transcriptome sequencing with downstream target enrichment, streamlining processes and reducing the substantial sample size and labor intensity typical of separate DNA and RNA workflows. This innovation plays a vital role in advancing precision medicine by improving biomarker discovery and deepening the understanding of diseases, particularly cancers.

Market Segmentation Overview for NGS in Precision Medicine
The report divides the next-generation sequencing in precision medicine market into several key segments:

By Product and Service:
- Sequencing Instruments
- Consumables and Reagents
- Library Preparation Kits
- Bioinformatics Software
- Next-Generation Sequencing (NGS) Services

By Technology:
- Whole Genome Sequencing (WGS)
- Whole Exome Sequencing (WES)
- Targeted Sequencing
- Ribonucleic Acid (RNA) Sequencing
- Single-Cell Sequencing

By Application:
- Oncology
- Infectious Disease
- Rare and Inherited Disorders
- Prenatal and Reproductive Health
- Pharmacogenomics

By End Use:
- Hospitals and Clinics
- Academic and Research Institutions
- Biopharmaceutical Companies
- Diagnostic Laboratories
- Contract Research Organizations (CROs)

Further subcategories include:

By Sequencing Instruments:
- Benchtop Sequencers
- High Throughput Sequencers

By Consumables and Reagents:
- Sequencing Reagents
- Sequencing Chips
- Flow Cells
- Sample Preparation Reagents

By Library Preparation Kits:
- DNA Library Preparation Kits
- RNA Library Preparation Kits
- Whole Genome Amplification Kits
- Target Enrichment Kits

By Bioinformatics Software:
- Data Analysis Software
- Data Management Software
- Sequence Alignment Software
- Variant Calling Software

By NGS Services:
- Whole Genome Sequencing Services
- Whole Exome Sequencing Services
- Targeted Sequencing Services
- RNA Sequencing Services
- Epigenomic Sequencing Services

This thorough segmentation enables a detailed understanding of the industry's scope and aids stakeholders in pinpointing specific areas of interest within the NGS in precision medicine market.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.